← Back to patent-cliff list
Inclisiran sodium
Tier C — Watch / tradeInclisiran sodium
Alnylam Pharmaceuticals Inc
Originator
2020
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：PCSK9
Brand：Leqvio
Indications (approved)：Hypercholesterolaemia, Hyperlipidaemia, Dyslipidaemia, 颈动脉疾病, Heterozygous familial hypercholesterolaemia, Atherosclerosis
Regional status
US
Approved
2021-12-22
EU
Approved
2020-12-09
China
Approved
2023-08-22
Japan
Approved
2023-09-25
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Inclisiran sodium?
Approved indications include: Hypercholesterolaemia, Hyperlipidaemia, Dyslipidaemia, 颈动脉疾病, Heterozygous familial hypercholesterolaemia, Atherosclerosis.
When does the Inclisiran sodium patent expire?
No public expiry year is available for Inclisiran sodium yet; this page updates once verified.
How do I get a quote for Inclisiran sodium intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27